Life-threatening Idiopathic Nonhistaminergic Acquired Angioedema With Response to Lanadelumab

J Investig Allergol Clin Immunol. 2024 Feb 22;34(1):68-70. doi: 10.18176/jiaci.0926. Epub 2023 Jul 5.

Authors

P Gamboa^{1

2}, C Galán¹, A Arrien¹, A Segurola^{1

2}, I Jáuregui^{1

2}

Affiliations

¹ Allergy Department, Hospital Universitario Cruces, Barakaldo, Spain.
² Biocruces Bizkaia Health Research Institute, Immunopathology Group, Barakaldo, Spain.

PMID: 37403773
DOI: 10.18176/jiaci.0926

No abstract available

Keywords: C1 inhibitor; Idiopathic bradykinergic angioedema; Landelumab.

MeSH terms

Angioedema* / drug therapy
Antibodies, Monoclonal, Humanized / therapeutic use
Humans

Substances

lanadelumab
Antibodies, Monoclonal, Humanized

Supplementary concepts

Acquired angioedema